Yan Leyfman: iPSC-derived CAR-NK cell therapy with three antitumor modalities
Yan Leyfman, Co-founder and Executive Director of MedNews Week, shared a post on LinkedIn about a recent paper by Armin Ghobadi et al. published in The Lancet:
“Fate Therapeutics Inc.’s (iPSC)-derived chimeric antigen receptor (CAR) natural killer (NK) cell therapy with 3 antitumour modalities: a CD19 CAR; a high-affinity, non-cleavable CD16 Fc receptor; and interleukin-15-interleukin-15 receptor fusion demonstrated efficacy in 86 patients after 4 prior lines of therapy with B-cell lymphoma.
Low grade CRS and no neurotoxicity observed.”
Authors: Armin Ghobadi, Veronika Bachanova, Krish Patel, Rebecca Elstrom, Paolo Strati et al.
Yan Leyfman MD, is the Co-founder and executive director of MedNews Week. He is also the Medical correspondent at OncLive. He is the Executive Committee Member at Music Beats Cancer.
He is a Clinical Researcher at Icahn School of Medicine at Mount Sinai. His research interests include oncology, Immunooncology, Cellular Therapy, and Immunotherapy.
More posts featuring Yan Leyfman.
-
ESMO 2024 Congress
September 13-17, 2024
-
ASCO Annual Meeting
May 30 - June 4, 2024
-
Yvonne Award 2024
May 31, 2024
-
OncoThon 2024, Online
Feb. 15, 2024
-
Global Summit on War & Cancer 2023, Online
Dec. 14-16, 2023